For most adults with diabetes, an A1C below 7% is the widely recommended target, but “optimal” shifts depending on your age, how long you’ve had diabetes, what other health conditions you live with, and even whether the A1C test itself is giving you an accurate reading. The American Diabetes Association sets that 7% benchmark as a reasonable goal for many people, while also acknowledging that some individuals benefit from tighter control and others are safer with a more relaxed target. Understanding where you fall on that spectrum matters more than chasing a single number.
Why Under 7% Became the Standard Target
The 7% threshold is not arbitrary. It traces back to large trials showing that the risk of damage to small blood vessels in the eyes, kidneys, and nerves climbs steeply as A1C rises above that neighborhood. Population data from the United States found that retinopathy prevalence increased sharply above an A1C of about 5.5%, rising roughly 13 percentage points for each additional 1% in A1C above that inflection point.1PubMed Central. Association of A1C and Fasting Plasma Glucose Levels With Diabetic Retinopathy Prevalence in the U.S. Population A large Swedish study of people with type 1 diabetes confirmed the pattern: compared to those with an average A1C between 6.5% and 6.9%, people with an A1C of 7.0–7.4% already had a higher risk of mild retinopathy and microalbuminuria, while the risk of severe complications like proliferative retinopathy and macroalbuminuria jumped once A1C exceeded about 8.6%.2BMJ. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
The relationship between A1C and these complications is continuous, meaning there is no magic cutoff where damage suddenly begins. But the 7% line sits at a practical sweet spot: below it, most people see meaningfully lower rates of eye, kidney, and nerve damage without an unacceptable burden of low blood sugar episodes. Data from the landmark Diabetes Control and Complications Trial showed that this risk reduction from lower glycemic exposure applied broadly across retinopathy, nephropathy, and neuropathy.3Diabetes. The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial
When Pushing Lower Backfires
If lower A1C protects small blood vessels, you might assume that driving it as low as possible would also prevent heart attacks and strokes. Several major trials tested exactly that, and the results were sobering. The ACCORD trial randomized people with type 2 diabetes and cardiovascular risk factors to either an aggressive A1C target below 6% or a standard target of 7–7.9%. The intensive arm had to be stopped early because participants in it were dying at a higher rate, primarily from cardiovascular causes.4PubMed Central. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials Two companion trials, ADVANCE and VADT, also found no significant reduction in cardiovascular events with intensive glucose lowering.
The ACCORD results held up over extended follow-up. Even after the intensive therapy was stopped and both groups were managed similarly, the group that had been pushed toward very low A1C levels still showed about 19% higher mortality over the entire observation period, alongside fewer nonfatal heart attacks.5PubMed. Long-term effects of intensive glucose lowering on cardiovascular outcomes A nine-year analysis confirmed the same pattern: the intensive strategy had a neutral effect on the overall cardiovascular composite but increased both cardiovascular and total mortality while reducing nonfatal heart attacks.6PubMed Central. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
The takeaway is not that lower blood sugar is bad. It’s that the methods used to get there, particularly in people who already have cardiovascular disease or long-standing diabetes, can cause more harm than good. Aggressive medication regimens increase the frequency of severe hypoglycemia, which is itself dangerous for the heart. This is why guidelines now emphasize individualization rather than a one-size-fits-all push toward the lowest possible number.
How Goals Shift for Older Adults
Older adults occupy a wide spectrum of health. A fit 68-year-old running half-marathons has very different needs from a frail 82-year-old with dementia and limited mobility. Guidelines recognize this. For healthy older adults without major comorbidities, targets similar to younger adults are generally appropriate. But for those who are frail, have significant cognitive or functional limitations, or carry a heavy burden of other illnesses, a target of under 8% or even 8.5% is considered reasonable.7Diabetes Care. 13. Older Adults: Standards of Care in Diabetes—2024 A systematic review of clinical practice guidelines found that most recommended a stricter target of under 7–7.5% for healthier older adults and a more relaxed target of under 8–8.5% for those who are frail or medically complex.8Age and Ageing. Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus
The reasoning is straightforward. The benefits of tight glucose control accumulate over years and even decades. Someone with a short life expectancy is unlikely to live long enough to see a meaningful reduction in vascular complications from bringing their A1C down from 8% to 7%. Meanwhile, the risks of treatment are immediate. A systematic review found that both very low A1C levels (below 6%) and very high levels (above 9%) were associated with worse outcomes in older adults, with the most favorable results clustering around 7.5–8%.9PubMed Central. Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes Severe hypoglycemia in older people can trigger falls, fractures, confusion, hospitalizations, and cardiac events, making the tradeoff between tight control and safety especially important.
Goals for Children and Adolescents
Children with type 1 diabetes have been subject to evolving targets over the years. Current ADA recommendations suggest an A1C below 7% for many children, with a strong emphasis on personalizing the goal. A higher target of under 7.5% may be more suitable for young children who cannot recognize or communicate symptoms of low blood sugar, or for families who do not have access to newer insulin formulations and diabetes technology. In some cases, an even more relaxed target of under 8% is warranted, such as when a child has a history of severe hypoglycemia or serious additional illnesses.10PubMed Central. The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence
On the other end, during the “honeymoon” period shortly after diagnosis, when the pancreas is still producing some insulin, or when newer technology allows very stable glucose control, a target below 6.5% can be safe and effective. The shift toward tighter targets in pediatrics has been driven partly by the availability of continuous glucose monitors and automated insulin delivery systems, which reduce the risk of dangerously low blood sugar episodes that historically made aggressive management too risky in children.
Pregnancy Demands Tighter Control
Pregnancy is one scenario where A1C targets tighten significantly. High blood sugar during pregnancy increases the risk of complications for both mother and baby, including preeclampsia, large-for-gestational-age infants, birth injuries, and neonatal hypoglycemia. For women with pre-existing diabetes who become pregnant, guidelines generally aim for an A1C below 6–6.5%, provided this can be reached without frequent hypoglycemia. The rationale is that even modest elevations in glucose during fetal development can have outsized effects.11PubMed Central. Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus
A1C has some limitations during pregnancy, though. Red blood cell turnover changes during pregnancy, and blood volume expands substantially, which can make A1C values less reflective of recent glucose patterns than they normally would be. For this reason, self-monitored blood glucose readings or continuous glucose monitor data often play a larger role in managing diabetes during pregnancy than A1C alone.
When A1C Itself Becomes Unreliable
A1C reflects average blood sugar over roughly the past two to three months by measuring how much glucose has attached to hemoglobin inside red blood cells. Anything that changes red blood cell lifespan or hemoglobin structure can distort the result, sometimes significantly.
Kidney Disease and Dialysis
People on hemodialysis have shorter red blood cell survival and receive erythropoietin to boost red cell production. Both factors pull A1C readings lower, creating a falsely reassuring picture. A study comparing diabetic patients on hemodialysis to diabetic patients without kidney disease found that A1C was significantly lower in dialysis patients despite their glucose and glycated albumin levels being higher. A1C was positively linked to hemoglobin levels and negatively linked to erythropoietin dose, meaning the drugs used to treat anemia in dialysis patients were themselves distorting the test.12PubMed. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis For this population, glycated albumin or fructosamine may give a more accurate snapshot of glucose control.
Iron Deficiency Anemia
In the opposite direction, iron deficiency can push A1C readings falsely high. When iron is low, red blood cells live longer on average, giving glucose more time to attach to hemoglobin. A study of iron-deficient individuals with controlled plasma glucose found their A1C averaged about 6.8%, elevated compared to controls, with an even higher reading in women.13PubMed Central. Influence of Iron Deficiency Anemia on Hemoglobin A1C Levels in Diabetic Individuals with Controlled Plasma Glucose Levels The mechanism is thought to involve both prolonged red cell survival and direct changes to hemoglobin structure that make it more prone to glycation.14PubMed Central. Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review This matters because iron deficiency is common, especially in women of reproductive age, and a falsely elevated A1C could lead to unnecessary medication intensification.
Racial and Ethnic Differences
A1C levels differ across racial and ethnic groups even after accounting for actual blood glucose levels. In the Diabetes Prevention Program, among participants with impaired glucose tolerance, Black participants had an adjusted mean A1C of about 6.18% compared to 5.78% for white participants, a gap that persisted after controlling for age, BMI, blood pressure, fasting glucose, insulin resistance, and other factors.15PubMed Central. Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program A cross-sectional analysis of two large studies found that A1C was roughly 0.4 to 0.5 percentage points higher in Black compared to white participants with diabetes after adjusting for plasma glucose and other characteristics.16PubMed. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies
These differences appear to be partly biological, involving variations in how readily hemoglobin becomes glycated, rather than purely reflective of glucose exposure. A study of over 2,000 patients with type 2 diabetes found that A1C was higher in Hispanic, Asian, and African patients compared to white patients even after adjustment, while an alternative glycemic marker showed the opposite pattern in some groups, suggesting the discrepancy lies in A1C biology rather than glucose control itself.17The Journal of Clinical Endocrinology & Metabolism. Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes The practical implication is that applying a single A1C cutoff uniformly to all groups may overdiagnose diabetes in some populations and underdiagnose it in others.
Prediabetes and Where the Risk Starts
Before diabetes is diagnosed, an A1C in the range of 5.7–6.4% is commonly labeled prediabetes. But this seemingly simple range hides meaningful variation in risk. Five different definitions of prediabetes are used in current practice, based on different cut points for A1C, fasting glucose, and two-hour glucose, and they do not all identify the same people.18PubMed Central. Prediabetes and What It Means: The Epidemiological Evidence
A cohort study examined what happens at different A1C thresholds within the prediabetes range and found striking differences. At the lower end (5.7–5.9%), the five-year risk of developing type 2 diabetes was only about 2%. At the upper end (6.2–6.4%), it jumped to roughly 26%.19PubMed Central. Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes That’s a thirteenfold difference within what gets reported to patients as a single diagnostic category. Someone with an A1C of 5.8% has a very different conversation ahead of them than someone at 6.3%, even though both technically have “prediabetes.” Lifestyle interventions and pharmacologic options can prevent or delay progression across this range, but the urgency and intensity of intervention differ considerably.
Time in Range as a Complementary Metric
A1C provides a useful average, but it’s blind to the swings happening throughout the day. Two people can have an identical A1C of 7% while having vastly different daily glucose patterns: one might hover steadily between 130 and 160 mg/dL, while the other careens from 50 to 300 mg/dL. Continuous glucose monitors have introduced a metric called “time in range,” the percentage of the day spent between 70 and 180 mg/dL, which captures this variability.
A1C and time in range are correlated but far from interchangeable. Data from the REPLACE trial found that the correlations among various continuous glucose monitor metrics were typically 0.90 or higher, but correlations of each of those metrics with A1C were lower, in the range of 0.66 to 0.78. For any given time-in-range percentage, there was a wide range of possible A1C values that could be associated with it.20PubMed Central. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c This means that managing diabetes by A1C alone can miss important information about how well glucose is actually controlled day to day. A general consensus target for time in range is above 70% for most adults with diabetes, with adjusted targets for older adults and those at high risk of hypoglycemia.
The Framework for Individualizing Your Target
Rather than memorizing a single number, the practical approach to A1C goals involves weighing a handful of patient-specific factors. Guidelines recommend determining the stringency of glycemic control based on your attitude and motivation, the risk of treatment-related hypoglycemia, how long you’ve had diabetes, life expectancy, existing complications, other medical conditions, and available resources.21Clinical Diabetes. Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens In general terms:
- Tighter targets (under 6.5–7%): Reasonable for people with short diabetes duration, long life expectancy, no significant cardiovascular disease, and access to therapies that carry low hypoglycemia risk.
- Standard target (under 7%): Appropriate for most adults as a starting point.
- Relaxed targets (under 8% or 8.5%): Appropriate for people with limited life expectancy, extensive complications, severe comorbidities, or situations where the harms of treatment outweigh the benefits.
The ADA explicitly notes that more aggressive targets are only recommended if they can be achieved safely and with an acceptable burden of therapy, and that less stringent goals are appropriate when the risks and burdens of treatment outweigh the potential benefits.22Diabetes Care. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022 This is a deliberate shift from the era when the implicit message was “lower is always better.”
Overtreatment and the Case for Pulling Back
One underappreciated problem in diabetes care is overtreatment: people, often older adults, whose A1C is well below their target while they remain on aggressive medication regimens that put them at risk for hypoglycemia. A cross-sectional study found that the rate at which clinicians actually reduced diabetes medication intensity was only about 25%, even when glucose levels were clearly lower than needed.23PubMed Central. A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study There is a clinical inertia that favors adding medications when glucose is high but rarely prompts removing them when glucose drops too low.
The evidence on deprescribing is encouraging. A scoping review found that reducing diabetes medications was successfully carried out in roughly 62–75% of participants with only small rises in A1C. Rates of deprescribing in older people with low A1C levels ranged from 14–27%, and reminder systems that flagged hypoglycemia led to less overtreatment and fewer low blood sugar episodes.24PubMed Central. Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review If your A1C is consistently below your target and you’re on medications that carry hypoglycemia risk, particularly sulfonylureas or insulin, it is worth having a conversation with your doctor about whether you’re taking more medication than you need.
Newer Medications Are Changing the Calculus
The conversation about A1C targets has been complicated, in a good way, by the arrival of drug classes that lower glucose while simultaneously protecting the heart and kidneys. SGLT2 inhibitors and GLP-1 receptor agonists have shown cardiovascular and renal benefits that appear partly independent of how much they lower A1C. Some experts have argued that these drugs should be considered second-line or even first-line therapy in patients with cardiorenal disease regardless of glycemic control.25The Lancet. What Is Optimal A1C? Goals by Age and Condition This means the traditional paradigm of choosing diabetes drugs primarily by their ability to lower A1C is giving way to a more holistic approach that weighs organ protection alongside glucose control.
For people making treatment decisions, the implication is that the choice of medication matters at least as much as the A1C number on your lab report. Two people with the same A1C of 7.5% may warrant different treatment strategies depending on whether they have heart failure, chronic kidney disease, or neither. The A1C target hasn’t become irrelevant, but it’s no longer the sole axis around which diabetes management rotates.
Why A1C Lab Results Vary Between Tests
If you’ve ever had two A1C results taken a few weeks apart come back slightly different, that’s not unusual and doesn’t necessarily mean your glucose control changed. The test itself has a degree of analytical variability. Significant improvements in measurement accuracy have occurred since glycated hemoglobin was first used clinically in the late 1970s, and international standardization programs have been developed to reduce variation between laboratories and methods.26PubMed Central. HbA1c standardisation: history, science and politics Still, a difference of 0.3–0.5% between two tests can fall within normal lab-to-lab variation, particularly if the tests were run at different facilities or using different assay methods. Clinicians generally look at trends over multiple readings rather than reacting to a single result, and you should too.
A1C is also reported in two sets of units worldwide: the traditional percentage used in the United States and the millimoles per mole (mmol/mol) system used in much of Europe and elsewhere. A 7% A1C corresponds to 53 mmol/mol. If you see your results reported in unfamiliar units, conversion tables are widely available, and your lab report will typically include the reference range for whichever unit system it uses.